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ISPOR 18 th Annual European Congress. 7-11 November 2015. Milan -Italy  Atrial Fibrillation (AF) is the most common arrhythmia in clinical practice with an estimated prevalence of 2.5% in the Portuguese population aged ≥40 years old. 1 AF has an important social impact in Portugal due to its associated mortality and morbidity being responsible for 3.8% of all deaths. In total, the burden of disease attributable to AF in 2013 was estimated at 23.084
Disability Adjusted Life Years (DALYs) and a total cost of €140 million, about 0.08% of the Portuguese gross domestic product. 2  Since August 2014 three non-Vitamin K antagonist oral anticoagulants (NOACs) have been reimbursed in Portugal for non valvular AF: dabigatran; rivaroxaban and apixaban. Each of these NOACs was considered to be costeffective versus the standard care (warfarin). 
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 The cardiovascular events considered were: ischemic stroke (mild, moderate, severe), hemorrhagic stroke (mild, moderate, severe), systemic embolism, other intracranial hemorrhage, other major bleeding, clinically relevant nonmajor bleeding, other cardiovascular hospitalization and cardiovascular death.
 NHS perspective was adopted. Costs and outcomes were discounted at a 5% annual rate, as recommended by Portuguese guidelines.  Apixaban has the highest drug acquisition cost due to higher adherence to treatment.
 Apixaban yielded to the highest life years gained and QALYs compared with the remaining NOACs and warfarin (Table 2) .
 Apixaban estimated ICER versus warfarin and dabigatran was 5,529€/QALY and 9,163€/QALY, respectively. Rivaroxaban is dominated, having less health gains and higher costs (Table 2 ).  Health states and events utility levels were the same as in Sullivan et al., 6 warfarin treatment was associated to an additional decrement. 7
Methods
Results
 Event-related, treatment and follow-up costs were estimated from National legislation, 2014 DRG database, experts opinion and National Authority of Medicines and Health Products (INFARMED) drug costs database.
 Model outputs included life years gained, quality-adjusted life years (QALYs), direct healthcare costs and incremental cost-effectiveness ratios (ICERs).
 One-way sensitivity analyses (e.g., different hazard ratios, stroke costs according to their severity, similar drop-out rates due to non-vascular events for all NOACs, different utilities and discount rates) and probabilistic analyses were performed to assess the robustness of the model and results.
a Intracranial hemorrage includes isquemic stroke and other intracranial hemorragies. Proportion of hemorragic stroke was 77, 64, 41 and 57% for apixaban, warfarin, dabigatran 110mg, dabigatran 150 and rivaroxabin respectively as in clinical trials ARISTOTLE 4 ; RE-LY 5 ; ROKET-AF. b Assumed same as apixaban. c Assumption due to few observation of systematic embolism.
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